Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of ...

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid competition ...

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

Novo Nordisk on Tuesday reported that its new obesity pill that targets the amylin hormone led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

In the study, overweight or obese patients without diabetes received increasing doses of amycretin, starting from 3 milligrams and up to a final dose of two 50 mg pills, Novo said. Patients who ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

There is a new chapter in Big Pharma’s billion-dollar war on obesity, as Novo Nordisk and Eli Lilly battle it out over the latest blockbuster drugs. Ozempic maker Novo Nordisk’s highly ...